Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Strictly Buy and Sell Set Ups -- Ignore unavailable to you. Want to Upgrade?

To: - with a K who wrote (2521)	3/1/2005 3:07:35 PM
From: chowder	Read Replies (1) \| Respond to of 13449

with a K, Great job! Congratulations. >>> Dabum has taught this dog well; many thanks! <<< And thanks for the kind words. Please keep me posted on your results as we go forward. dabum

To: - with a K who wrote (2521)	3/3/2005 2:22:58 AM
From: - with a K	Respond to of 13449

Feeling frisky, I added to CTIC AH. Cell Therapeutics calls busy ahead of Xyotax data 4:07 p.m. 03/02/2005 Provided by CHICAGO, March 2 (Reuters) - Investors were piling into the call options on Cell Therapeutics Inc. (CTIC) on Wednesday, amid speculation the biotechnology company's clinical trial data for lung cancer drug Xyotax would be positive, one options analyst said. The company could not immediately be reached for comment. Shares of Seattle-based Cell Therapeutics ended 8.6 percent higher at $10.49 on the Nasdaq on Wednesday. "Cell Therapeutics traded down after earnings Monday, but today's action is speculation on the drug tests being positive," said Jon Najarian, chief market strategist at PTI Securities, an online options and securities broker based in Chicago. Xyotax links paclitaxel, the generic version of the cancer drug Taxol, to a substance that binds to tumors, allowing higher levels of the chemotherapy agent to be trapped in the tumor while reducing the level affecting healthy tissue. "Traders say the company confirmed for them the release date of early March rather than mid-March, which explains the heavy volume in March options," Najarian said. Cell Therapeutics said on Tuesday that trial results would be announced in the first half of March. Chief Executive James Bianco said in a statement that the company was analyzing the results of three phase III trials of Xyotax in lung cancer for the potential submission of a U.S. Food and Drug application later this year. Among the most active options were the calls that give the right to buy the stock at $10, $12.50 and $15 by mid-March. By late Wednesday, a total of roughly 91,433 calls and 11,642 puts traded on the company across the U.S. option exchanges, outpacing Tuesday's combined tally of 77,083 contracts, according to market research firm Track Data. A big chunk of the call volume was in the March 12.5 calls which traded 22,846 contracts, compared with open interest of 26,265 contracts. In the March 15 and March 10 calls, a total of more than 23,000 calls changed hands. "Investors were bidding up these calls as demonstrated by explosive volatility in all three strikes. They were buying these calls on the hope that would be positive trial results of Xyotax," Najarian said.